Evrysdi Generic Name & Formulations
Risdiplam 60mg; pwd for oral soln (providing 0.75mg/mL) after constitution; contains mannitol, sucralose; strawberry flavor.
Survival motor neuron 2 (SMN2) splicing modifier.
Bottle (80mL)—1 (w. adapter, oral syringes)
Spinal muscular atrophy (SMA).
Evrysdi Dosage and Administration
Adults and Children
Must be administered immediately after drawn up into the oral syringe. Take once daily after a meal at same time each day. May be given via nasogastric or gastrostomy tube if unable to swallow. <2months: 0.15mg/kg. 2months–<2yrs: 0.2mg/kg. ≥2yrs (<20kg): 0.25mg/kg; (≥20kg): 5mg. Breastfed infants: administer after breastfeeding; do not mix with formula or milk.
Evrysdi Boxed Warnings
Avoid inhalation and direct contact with skin or mucous membranes with dry powder and constituted solution. Hepatic impairment: avoid. Pregnancy: exclude status prior to initiation. Advise females of reproductive potential to use effective contraception during and for ≥1 month after the last dose. Possible male infertility. Nursing mothers.
Avoid concomitant with MATE substrates (eg, metformin); if unavoidable, monitor for drug-related toxicities; consider dose reduction of substrate.
Evrysdi Adverse Reactions
Late-onset: fever, diarrhea, rash; Infantile-onset: also upper respiratory tract infection, pneumonia, constipation, vomiting.
Evrysdi Clinical Trials
Evrysdi Patient Counseling